带有 C 末端组氨酸和 Avi 标签

NR-56447?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.529 Lineage (Omicron Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.529 Lineage (Omicron Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.529 Lineage (Omicron Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-56447.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), B.1.1.529 lineage (Omicron variant) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-56447 lacks the signal sequence and contains 1193 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-56447 includes A67V, delH69-V70, T95I, G142D, delV143-Y145, delN211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-56447 has a theoretical molecular weight of 139,900 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer and, when bound to a host receptor, allows fusion of the viral and cellular membranes. B.1.1.529 is one of several lineages and sublineages designated Omicron by the World Health Organization (WHO) and was first identified in South Africa, followed by multiple countries in November 2021. This lineage contains multiple mutations in the receptor-binding domain (RBD) that have been identified in other variants, including K417N, N501Y and D614G. The presence of D614G among variants has been shown to increase transmissibility, with K417N, Q493R, N501Y and Y505H shown to be important residues mediating virus entry into host cells. E484A has been shown to decrease neutralization by post-vaccination sera and some monoclonal antibody treatments. Each vial contains approximately 100 microliters of NR-56447 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).

NR-55712?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.621 Lineage (Mu Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.621 Lineage (Mu Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.621 Lineage (Mu Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55712.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), B.1.621 lineage (Mu variant) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55712 lacks the signal sequence and contains 1197 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55712 includes T95I, insert143T, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55712 has a theoretical molecular weight of 139,700 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. B.1.621 is one of several lineages and sublineages designated Mu by the World Health Organization (WHO) and was first identified in Columbia in January 2021. This lineage contains several key mutations of importance to the S glycoprotein: the E484K mutation has been identified in escape mutants from convalescent antisera, and is thought to play a role in the loss of antibody neutralizing activity; N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence; D614G, which is common to the current variants of interest and concern identified by the Centers for Disease Control and Prevention (CDC), was one of the first documented in the U.S. in the initial stages of the pandemic and demonstrates evidence of increasing virus transmissibility; and mutation P681H, part of the S1/S2 proteolytic cleavage site for furin proteases, results in increased cleavage efficiency and may alter antibody recognition sites. Each vial contains approximately 100 ?L of NR-55712 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA). Additional information and tools are available at ViPR (Virus Pathogen Resource).

NR-55711?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, AY.2 Lineage (Delta Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, AY.2 Lineage (Delta Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-70°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, AY.2 Lineage (Delta Variant) with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55711.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), AY.2 Lineage (Delta Variant) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55711 lacks the signal sequence and contains 1194 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag^? BirA biotinylation acceptor sequence. NR-55711 includes T19R, V70F, G142D, E156G, delF157-R158, A222V, K417N, L452R, T478K, D614G, P681R and D950N mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55711 has a theoretical molecular weight of 139,600 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. AY.2 is one of several lineages and sublineages designated Delta by the World Health Organization (WHO) and was first identified in India. This lineage contains multiple mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD), such as L452R which has already been identified in other variants. The L452R mutation has been shown to decrease sensitivity to neutralizing antibodies, increase viral infectivity and enhance viral replication capacity. Each vial contains approximately 100 microliters of NR-55711 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA). The concentration, expressed as milligrams per milliliter, is shown on the Certificate of Analysis.

NR-55615?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55615.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), B.1.1.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55615 lacks the signal sequence and contains 1189 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55615 includes G75V, T76I, del246-252 (RSYLTPG), D253N, L452Q, F490S, D614G and T859N mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55615 has a theoretical molecular weight of 138,900 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The B.1.1.1 lineage includes the sublineage C.37, designated Lambda by the World Health Organization (WHO) and first identified in Peru. The B.1.1.1 lineage is characterized by a novel deletion (del246-252) and mutations including L452Q and F490S in the S glycoprotein Receptor Binding Domain (RBD). These deletions and mutations may contribute to increased transmissibility. Each vial contains approximately 100 ?L of NR-55615 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA). Additional information and tools are available at ViPR (Virus Pathogen Resource).

NR-55311?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.7 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.7 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.1.7 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55311.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), United Kingdom variant (UK; B.1.1.7 lineage) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55311 lacks the signal sequence and contains 1193 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55311 is derived from the B.1.1.7 lineage of SARS-CoV-2, which includes del69-70, del144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55311 has a theoretical molecular weight of 139,500 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2, UK variant (B.1.1.7 lineage) has been solved at 3.22 ? resolution (PDB: 7LWS). The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The UK variants of SARS-CoV-2 include multiple mutations that were first identified in the United Kingdom, and the most studied is N501Y. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. Each vial contains approximately 100 ?L of NR-55311 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA). Additional information and tools are available at ViPR (Virus Pathogen Resource).